Activating c-KIT mutations have been indentified in various human cancers. c-KIT exon 8 and 17 mutations have been described in patients with CBF-AMLs and usually confer a poor prognosis with increased relapse rate.

C-kit may also be found in higher than normal amounts, or in a changed form, on some types of cancer cells, including gastrointestinal stromal tumors and melanoma. Measuring the amount of c-kit in tumor tissue may help diagnose cancer and plan treatment.

Among these CSC markers, c-kit is the most commonly used [8–11] because c-kit positive (c-kit+) cells have been shown to differentiate into cardiac cells including cardiomyocytes, vascular smooth muscle cells, and endothelial cells [8,42]

C-kit mutation analysis is a genetic test that detects mutations in the c-kit gene, also known as the KIT proto-oncogene. Mutations in the c-kit gene can be associated with various malignancies, particularly gastrointestinal stromal tumors (GISTs), melanomas, and certain types of leukemia. Here's how to interpret the results of a c-kit mutation analysis test: Presence of Mutations: If mutations are detected in the c-kit gene, it suggests that the patient's tumor or disease may be driven by aberrant activation of the c-kit signaling pathway. The specific type and location of the mutations detected can provide additional information about the prognosis, treatment response, and potential therapeutic targets. Type of Mutation: Different types of mutations in the c-kit gene may have varying effects on protein function and clinical outcomes. Gain-of-function mutations, such as point mutations or small insertions/deletions, can result in constitutive activation of the c-kit protein, leading to uncontrolled cell growth and proliferation. Loss-of-function mutations, such as large deletions or truncating mutations, may disrupt normal c-kit signaling and have different implications for tumor behavior and treatment response. Association with Specific Diseases: In GISTs, mutations in the c-kit gene are common and are considered driver mutations that contribute to tumor development and progression. In melanomas, mutations in the c-kit gene are less common but may be present, particularly in certain subtypes of melanoma. In leukemia, mutations in the c-kit gene may be associated with specific subtypes, such as core-binding factor acute myeloid leukemia (AML). Clinical Correlation: Interpretation of c-kit mutation analysis results should be done in conjunction with the patient's clinical history, imaging studies, histopathological findings, and other relevant diagnostic tests. The presence of c-kit mutations may influence treatment decisions, including the selection of targeted therapies such as tyrosine kinase inhibitors (e.g., imatinib) that specifically inhibit c-kit signaling. Prognostic and Therapeutic Implications: The presence of certain c-kit mutations may have prognostic significance and impact patient outcomes. Targeted therapies directed against c-kit mutations have shown efficacy in specific cancer types, particularly GISTs, where imatinib has revolutionized treatment and significantly improved survival outcomes. Follow-Up: Patients with c-kit mutations may require long-term monitoring to assess treatment response, disease progression, and the emergence of resistance mutations. Interpretation of c-kit mutation analysis results should be performed by healthcare professionals experienced in molecular diagnostics, oncology, and cancer genetics. Treatment decisions should be individualized based on the specific mutation profile, tumor characteristics, patient preferences, and available treatment options. Close collaboration between oncologists, pathologists, and molecular geneticists is essential to optimize patient care and outcomes.

Blood